Killing multiple myeloma cells with the small molecule 3-bromopyruvate: Implications for therapy

Anti-Cancer Drugs

Volumn 25, Issue 6, 2014, Pages 673-682

  Majkowska Skrobek, Grayna ^a   Augustyniak, Daria ^a   Lis, Paweł ^a   Bartkowiak, Anna ^a   Gonchar, Mykhailo ^b   Ko, Young H ^c   Pedersen, Peter L ^d   Goffeau, Andre ^e   Ułaszewski, Stanisław ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b INSTITUTE OF CELL BIOLOGY   (Ukraine)

^c UM BioPark   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

3 bromopyruvate; A new class of anticancer agents; Energy blocker; Glivec Gleevec; Multiple myeloma; Mutagenicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BROMOPYRUVIC ACID; BUTHIONINE SULFOXIMINE; IMATINIB; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; BROMOPYRUVATE; COTRANSPORTER; GLUTATHIONE; LACTIC ACID; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRUVIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG UPTAKE; GENE; HUMAN; HUMAN CELL; IC 50; MCT1 GENE; MULTIPLE MYELOMA; MUTAGENICITY; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; GENETICS; IC50; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BENZAMIDES; BUTHIONINE SULFOXIMINE; CELL SURVIVAL; GLUTATHIONE; HUMANS; INHIBITORY CONCENTRATION 50; LACTIC ACID; MONOCARBOXYLIC ACID TRANSPORTERS; MULTIPLE MYELOMA; PIPERAZINES; PYRIMIDINES; PYRUVATES; SYMPORTERS; TUMOR CELLS, CULTURED;

EID: 84901587673     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000094     Document Type: Article

References (48)

1. Ko YH, McFadden BA. Alkylation of isocitrate lyase from Escherichia coli by 3-bromopyruvate. Arch Biochem Biophys 1990; 278:373-380. (Pubitemid 20126065)
2. Pedersen PL. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective ''small molecule'' anti-cancer agent taken from labside to bedside: Introduction to a special issue. J Bioenerg Biomembr 2012; 44:1-6.
3. Rodrigues-Ferreira C, Pereira da Silva AP, Galina A. Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: Role of mitochondrially bound hexokinase. J Bioenerg Biomembr 2012; 44:39-49.
4. Shoshan MC. 3-Bromopyruvate: Targets and outcomes. J Bioenerg Biomembr 2012; 44:7-15.
5. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: Characterization and targeting hexokinase. Cancer Lett 2001; 173:83-91. (Pubitemid 32907513)
6. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, et al. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004; 5:269-275. (Pubitemid 39311489)
7. Pedersen PL. Warburg, me and hexokinase-2: Multiple discoveries of key molecular events underlying one of cancers most common phenotypes, the ''Warburg Effect'', i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 2007; 39:211-222. (Pubitemid 47619382)
8. Buijs M, Vossen JA, Geschwind JF, Ishimori T, Engles JM, Acha-Ngwodo O, et al. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs 2009; 27:120-123.
9. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: Cancer's stygian link to the '' Warburg effect'' and a pivotal target for effective therapy. Semin Cancer Biol 2009; 19:17-24.
10. Mathupala SP, Ko YH, Pedersen PL. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 2010; 1797:1225-1230.
11. Schaefer NG, Geschwind JF, Engles J, Buchanan JW,Wahl RL. Systematic administration of 3-bromopuruvate in treating disseminated aggressive lymphoma. Transl Res 2012; 1:51-57.
12. El Sayed SM, Abou El-Mad RM, Shishido Y, Yorita K, Chung SP, Tran DH, et al. D-Amino acidoxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects. J Bioenerg Biomembr 2012; 44:513-523.
13. Barille-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, et al. Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program 2003; 1:248-278.
14. Boersma-Vreugdenhil GR, Kuipers J, Van Stralen E, Peeters T, Michaux L, Pearson PL, et al. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: A molecular and genetic analysis of the chromosomal breakpoint. Br J Haematol 2004; 126:355-363. (Pubitemid 39005715)
15. Dolloff NG, Talamo G. Targeted therapy of multiple myeloma. Adv Exp Med Biol 2013; 779:197-221.
16. Cavazzini F, Hernandez JA, Gozzetti A, Russo Rossi A, De Angeli C, Tisco R, et al. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol 2008; 142:529-537. (Pubitemid 352020210)
17. Deleu S, Lemaire M, Arts J, Menu E, Valckenborgh E, Vande Broek I, et al. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: Effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 2009; 69:5307-5311.
18. Deweerdt S. Towards a myeloma mouse. Nature 2011; 480:28-29.
19. Nakano A, Tsuji D, Miki H, Cui Q, El Sayed SM, Ikegame A, et al. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One 2011; 6:e27222.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63. (Pubitemid 14203433)
21. Gutmann I, Wahlefeld WL. (+)-Lactate determination with lactate dehydrogenase and NAD. In: Bergmeyer HU, editor. Methods of enzymatic analysis. New York: Academic Press; 1974; p. 1464.
22. Kobayashi M, Fujita I, Itagaki S, Hirano T, Iseki K. Transport mechanism for L-lactic acid in human myocytes using human prototypic embryonal rhabdomyosarcoma cell line (RD cells). Biol Pharm Bull 2005; 28:1197-1201. (Pubitemid 41327585)
23. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: Minimum information for publication of quantitative real-Time PCR experiments (special report). Clin Chem 2012; 55:611-622.
24. Ames B, Lee F, Durston W. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc Natl Acad Sci USA 1973; 70:782-786.
25. Yahagi T, Nagao M, Seino Y, Matsushima T, Sugimura T. Mutagenicities of N-nitrosamines on Salmonella. Mutat Res 1977; 48:121-129.
26. Quin JZ, Xin H, Nickoloff BJ. 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Biochem Biophys Res Commun 2010; 396:495-500.
27. Dusre L, Mimnaugh G, Myers CE, Sinha BK. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res 1989; 49:511-515. (Pubitemid 19050305)
28. Casal M, Paiva S, Andrade RP, Gancedo C, Leäo C. The lactate-proton symport of Saccharomyces cerevisiae is encoded by Jen1. J Bacteriol 1999; 181:2620-2623. (Pubitemid 29181589)
29. Lis P, Zarzycki M, Ko HY, Casal M, Pedersen P, Goffeau A, et al. Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae. J Bioenerg Biomembr 2012; 44:155-161.
30. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet 2013; 45:104-108.
31. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: State of the art. J Bioenerg Biomembr 2012; 44:127-139.
32. Queiró s O, Presto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, et al. Butytrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. J Bioenerg Biomembr 2012; 44:141-153.
33. Torres de Oliveira AT, Pinheiro C, Longatto-Filho A, Brito MJ, Martinho O, Matos D, Carvalho AL. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr 2012; 44:171-178.
34. Reliene R, Schiest RH. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis 2006; 27:240-244. (Pubitemid 43159875)
35. Diaz-Ruiz R, Uribe-Carvajal S, Devin A, Rigoulet M. Tumor cell energy metabolism and its common features with yeast metabolism. Biochim Biophys Acta 2011; 1796:252-265.
36. Diaz-Ruiz R, Rigoulet M, Devin A. The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim Biophys Acta 2011; 1807:568-576.
37. Ganapathy-Kanniappan S, Geschwind JFH, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 2009; 29:4909-4918.
38. Kim W, Yoon JH, Jeong JM, Cheon GJ, Lee TS, Yang JI, et al. Apoptosisinducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 2007; 6:2554-2562. (Pubitemid 47480421)
39. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42:1007-1017. (Pubitemid 32645780)
40. De Moraes AC, Maranho CK, Rauber GS, Santos-Silva MC. Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy. J Clin Lab Anal 2013; 27:62-71.
41. Goffeau A. Drug resistance: The fight against fungi. Nature 2008; 452:541-542. (Pubitemid 351483350)
42. Dylag M, Lis P, Niedzwiecka K, Ko YH, Pedersen PL, Goffeau A, et a.l. -Bromopyruvate: A novel antifungal agent against the human pathogen Cryptococcus neoformans. Biochem Biophys Res Commun 2013; 434:322-327.
43. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL. A translational study ''case report'' on the small molecule ''energy blocker'' 3-bromopyruvate (3BP) as a potent anticancer agent: From bench side to bedside. J Bioenerg Biomembr 2012; 44:163-170.
44. Novartis Pharma AG. Gleevecs (imatinib mesylate) tablets prescribing information. East Hanover, NJ; 2006 Sep. Anon. Drugs of choice for cancer. Treat Guidel Med Lett 2003; 1:41-52.
45. Ko YH, Delannoy M, Hullihen J, Chiu W, Pedersen PL. Mitochondrial ATP synthasome. Cristae-enriched membranes and a multiwell detergent screening assay yield dispersed single complexes containing the ATP synthase for Pi and ADP/ATP. J Biol Chem 2003; 278:12305-12309. (Pubitemid 36800213)
46. Chen C, Ko Y, Delannoy M, Ludtke SJ, Chiu W, Pedersen PL. Mitochondrial ATP synthasome: Three-dimensional structure by electron microscopy of the ATP synthase in complex formation with carriers for Pi and ADP/ATP. J Biol Chem 2004; 279:31761-31768. (Pubitemid 39037848)
47. Wittig I, Schägger H. Structural organization of mitochondrial ATP synthase. Biochim Biophys Acta 2008; 1777:592-598.
48. Seyfried T. Cancer as a metabolic disease. Hoboken, New Jersey: Wiley; 2012..